Article
Cell Biology
Lina Wang, Dongrun Tang, Tong Wu, Fengyuan Sun
Summary: LTBP4 down-regulation in melanoma serves as an independent prognostic factor for patient survival, while inhibition of LTBP4 promotes cell proliferation and metastasis in melanoma cells.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Siyuan Chen, Bo Ning, Jinwen Song, Zihan Yang, Li Zhou, Zhiji Chen, Linhong Mao, Hongtao Liu, Qingliang Wang, Song He, Zhihang Zhou
Summary: Acidic microenvironment promotes proliferation and metastasis of pancreatic cancer cells by inhibiting AMPK/Hippo signaling and upregulating MMP1 expression.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES
(2022)
Review
Oncology
Qinyu Han, Shi Qiu, Huiwen Hu, Wenjing Li, Xiangguo Dang, Xiangqi Li
Summary: Bone is the most common site of metastasis from breast cancer, causing significant impact on patients' quality of life and mortality. The molecular mechanism of breast cancer cells metastasizing to bone involves the complex interaction between cancer cells and the bone microenvironment, although the exact mechanism is not yet clear. Recent studies have highlighted the significance of the Hippo signaling pathway in breast cancer metastasis, especially in bone metastasis, although the specific molecular mechanism remains to be fully understood. This review discusses the role of the Hippo signaling pathway in breast cancer metastasis, particularly in bone metastasis, to establish a solid theoretical foundation for further research and the development of targeted therapies.
FRONTIERS IN ONCOLOGY
(2023)
Article
Agronomy
Yi Chen, Jiachang Sun, Yingying Wei, Kefeng Cao, Shu Jiang, Xingfeng Shao
Summary: This study reveals the regulatory mechanism of PpZAT10 on vacuolar invertase VIN2 in peach fruit, influencing sucrose metabolism through transcriptional regulation and protein-protein interaction.
POSTHARVEST BIOLOGY AND TECHNOLOGY
(2022)
Article
Cell Biology
Danrong Ye, Yuying Wang, Xiaochong Deng, Xiqian Zhou, Diya Liu, Baian Zhou, Wenfang Zheng, Xuehui Wang, Lin Fang
Summary: Breast cancer is a common malignant tumor in women and understanding its mechanisms is important for prognosis. Recent research suggests that dermatopontin (DPT), an extracellular matrix protein, is involved in cancer development. This study found that DNMT3a-mediated DPT promoter hypermethylation leads to downregulation of DPT in breast cancer, and low DPT expression is associated with poor prognosis. Additionally, DPT interacts with YAP to inhibit breast cancer growth and metastasis. These findings reveal the critical role of DPT in breast cancer progression and suggest potential targeted therapies.
CELL DEATH & DISEASE
(2023)
Article
Oncology
Wang Zeng, Shuchen Gu, Yi Yu, Yili Feng, Mu Xiao, Xin-Hua Feng
Summary: EMT is a crucial biological process, and ZNF451 plays a role in promoting EMT by regulating TWIST2 through SUMOylation to increase TWIST2 protein levels in cells.
AMERICAN JOURNAL OF CANCER RESEARCH
(2021)
Review
Oncology
Hong-Li Li, Qian-Yu Li, Min-Jie Jin, Chao-Fan Lu, Zhao-Yang Mu, Wei-Yi Xu, Jian Song, Yan Zhang, Sai-Yang Zhang
Summary: The Hippo pathway can promote tumor invasion and metastasis by regulating the expression of target genes. YAP/TAZ, as the core molecules of the Hippo pathway, interact with TEADs to regulate the expression of target genes related to tumor metastasis and invasion. Target genes induced by YAP/TAZ can lead to invasive pseudopodia formation, reduced intercellular adhesion, ECM degradation, EMT, or indirectly promote invasion and metastasis through other signaling pathways.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2021)
Article
Oncology
Jianxin Xu, Xuejiao Fang, Luye Long, Sixuan Wang, Shihan Qian, Jianxin Lyu
Summary: This study found that HMGA2 is highly expressed in TNBC cells, and downregulation of HMGA2 inhibits the migration and invasion of TNBC, as well as tumor metastasis in vivo, through suppression of EMT and the Hippo-YAP pathway.
CANCER BIOLOGY & THERAPY
(2021)
Article
Horticulture
Fang Cheng, Jinyong Huang, Peipei Tang, Yan Li, Zongli Hu, Baolu Cui, Xiaodong Xie, Qiyan Chen, Jianwei Tian, Huihui Gu, Caipeng Yue, Jingnan Zhang, Yanjie Zhang, Guoping Chen
Summary: During storage, transportation, and sales, the deterioration of tomato ripening fruit caused by mechanical damage and microbial infection leads to significant economic losses. This study isolated and studied the SlCHYR1 gene, which encodes a protein containing a RING and CHY zinc finger domain, showing high expression levels in tomato fruit. Overexpression of SlCHYR1 accelerates fruit ripening, reduces shelf life, and inhibits chlorophyll accumulation in tomato fruit. Further investigation reveals that SlCHYR1 promotes tomato fruit ripening through abscisic acid and ethylene production and signaling.
SCIENTIA HORTICULTURAE
(2022)
Article
Oncology
Ching-Hu Wu, Chien-Wei Feng, Chiu-Lin Wang, Zhi-Hong Wen, Cheng-Yu Long, Feng-Hsiang Tang
Summary: Our data showed that cisplatin treatment induces production of reactive oxygen species (ROS) that regulate apoptotic protein expression and stimulate anti-oxidative signal, inhibiting cell migration. The intervention of Zfp90 enhanced apoptosis pathway and inhibited migrative pathway, thus regulating the sensitivity of ovarian cancer cells to cisplatin. This study suggests that loss of Zfp90 function promotes cisplatin sensitization in ovarian cancer cells through the regulation of Nrf2/HO-1 pathway, enhancing cell apoptosis and inhibiting migration.
Article
Cell Biology
Juanjuan Xiao, Lu Zhang, Huijun Yi, Ling Zou, Jianmei Mo, Feng Xue, Jinhua Zheng, Yingze Huang, Hui Lu, Hansheng Wu, Peipei Xue, Xin Zhang, Lifei He, Zhaoxin Li, Shigui Pang, Guibin Qiao, Qiuhong Duan, Feng Zhu
Summary: This study reveals the role of T-LAK cell-oriented protein kinase (TOPK) in anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). The researchers found that TOPK is highly expressed in ALK-positive NSCLC and identified ALK as an upstream kinase of TOPK. Moreover, they showed that inhibiting TOPK enhances tumor sensitivity to an ALK inhibitor, and the combination of alectinib and a TOPK inhibitor suppresses tumor growth and promotes apoptosis of ALK-positive NSCLC cells.
CELL DEATH & DISEASE
(2022)
Article
Cell Biology
Chunlei Guo, Shuang Li, Ang Liang, Mengchao Cui, Yunwei Lou, Hui Wang
Summary: PPA1 is highly expressed in breast cancer and correlated with poor survival in patients. Silencing PPA1 can inhibit breast cancer proliferation and metastasis. PPA1 serves as an activator of the PI3K/AKT/GSK3 beta/Slug-mediated breast cancer progression and is a potential therapeutic target for inhibiting tumor progression.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Article
Medicine, Research & Experimental
Hyun Jeong Seok, Young Eun Choi, Jae Yeon Choi, Joo Mi Yi, Eun Joo Kim, Mi Young Choi, Su-Jae Lee, In Hwa Bae
Summary: Breast cancer is the most common female cancer worldwide, with difficulties in treatment due to unknown mechanisms. Research suggests that miRNA can serve as effective biomarkers for various diseases, including cancer. The study found that miR-5088-5p, promoted by Fyn, is involved in the malignancy of breast cancer.
MOLECULAR THERAPY-NUCLEIC ACIDS
(2021)
Article
Biochemistry & Molecular Biology
Stefania Scicchitano, Maria Concetta Faniello, Maria Mesuraca
Summary: The human zinc finger protein 521 (ZNF521) plays a crucial role in the regulation of human ovarian cancer, affecting proliferation, progression, and cancer stem cell properties. This study also reveals the influence of ZNF521 on the NRF2-NOTCH signaling pathway in ovarian cancer.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Biochemistry & Molecular Biology
Xigan He, Jinggui Chen, Jiamin Zhou, Anrong Mao, Weiqi Xu, Hongxu Zhu, Qi Pan, Yiming Zhao, Ning Zhang, Longrong Wang, Miao Wang, Zeyang Liu, Weiping Zhu, Lu Wang
Summary: This study identified a newly found lncRNA, EWSAT1, which plays a crucial role in hepatocellular carcinoma (HCC) metastasis. EWSAT1 is significantly upregulated in HCC and is associated with an aggressive phenotype and low patient survival. It promotes proliferation and metastasis of HCC cells by activating the transcription of cancer-related genes through the Hippo-YAP signaling pathway.
Article
Oncology
Hong-xia Tian, Zhi-hong Chen, Guang-Ling Jie, Zhen Wang, Hong-hong Yan, Si-pei Wu, Shui-lian Zhang, Dan-xia Lu, Xu-chao Zhang, Yi-long Wu
Summary: This study investigated the characteristics and prognostic features of the NF1 gene in EGFR mutant lung cancer patients. The results showed that NF1 mutations were enriched in older, male, and smoking patients, and were mutually exclusive with TP53, BRAF, and RASA1 mutations. TP53 mutation worsened the prognosis in cases of NF1 mutant or EGFR/NF1 co-mutant lung adenocarcinomas. NF1 mutations were not associated with overall survival in lung adenocarcinoma patients, but NF1/EGFR co-mutation patients had a longer overall survival than those with a single mutation of either gene. Furthermore, NF1 mutations significantly prolonged overall survival in EGFR mutant/TP53 wild-type patients but not in patients with EGFR/TP53 co-mutations.
Article
Oncology
Gilberto de Castro Jr, Iveta Kudaba, Yi-Long Wu, Gilberto Lopes, Dariusz M. Kowalski, Hande Z. Turna, Christian Caglevic, Li Zhang, Boguslawa Karaszewska, Konstantin K. Laktionov, Vichien Srimuninnimit, Igor Bondarenko, Kaoru Kubota, Rinee Mukherjee, Jianxin Lin, Fabricio Souza, Tony S. K. Mok, Byoung Chul Cho
Summary: This study presented the 5-year results of the KEYNOTE-042 trial, which showed that pembrolizumab demonstrated long-term clinical benefit compared to chemotherapy in patients with PD-L1-positive, locally advanced/metastatic non-small-cell lung cancer. Regardless of the level of PD-L1 expression, pembrolizumab had a better overall survival rate, confirming its status as a standard of care for this patient population.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Parneet Cheema, Byoung Chul Cho, Helano Freitas, Mariano Provencio, Yuh Min Chen, Sang-We Kim, Yi-Long Wu, Antonio Passaro, Claudio Martin, Marcello Tiseo, Gee-Chen Chang, Keunchil Park, Benjamin Solomon, Otto Burghuber, Janessa Laskin, Ziping Wang, Sung Yong Lee, Yanping Hu, Johan Vansteenkiste, He-long Zhang, Emer Hanrahan, Thomas Geldart, Rosemary Taylor, Leslie Servidio, Jingyi Li, Filippo de Marinis
Summary: This study reports the final analysis from ASTRIS, the largest real-world study of osimertinib in patients with advanced/metastatic EGFR T790M NSCLC. The results demonstrate the clinical benefit and safety of osimertinib in this patient population.
Article
Oncology
Roy S. Herbst, Yi-Long Wu, Thomas John, Christian Grohe, Margarita Majem, Jie Wang, Terufumi Kato, Jonathan W. Goldman, Konstantin Laktionov, Sang-We Kim, Chong-Jen Yu, Huu Vinh Vu, Shun Lu, Kye Young Lee, Guzel Mukhametshina, Charuwan Akewanlop, Filippo de Marinis, Laura Bonanno, Manuel Domine, Frances A. Shepherd, Damien Urban, Xiangning Huang, Ana Bolanos, Marta Stachowiak, Masahiro Tsuboi
Summary: The study demonstrates that adjuvant osimertinib provides a prolonged disease-free survival (DFS) benefit, reduces the risk of recurrence, improves central nervous system (CNS) DFS, and has a consistent safety profile in resected EGFR-mutated NSCLC.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Guang-Ling Jie, Lun-Xi Peng, Mei-Mei Zheng, Hao Sun, Song-Rong Wang, Si-Yang Maggie Liu, Kai Yin, Zhi-Hong Chen, Hong-Xia Tian, Jin-Ji Yang, Xu-Chao Zhang, Hai-Yan Tu, Qing Zhou, Catherine C. L. Wong, Yi-Long Wu
Summary: This study explores the clinical utility of plasma proteomics-derived biomarkers for MET-dysregulated NSCLC patients treated with MET inhibitors. Mass spectrometry analysis of longitudinal plasma samples revealed that the peripheral plasma proteomic characteristics were associated with treatment outcomes. A four-protein signature (MYH9, GNB1, ALOX12B, and HSD17B4) was identified as a high-accuracy predictor of response and progression-free survival in patients treated with MET inhibitors.
Article
Multidisciplinary Sciences
Juliann Chmielecki, Tony Mok, Yi-Long Wu, Ji-Youn Han, Myung-Ju Ahn, Suresh S. Ramalingam, Thomas John, Isamu Okamoto, James Chih-Hsin Yang, Frances A. Shepherd, Krishna C. Bulusu, Gianluca Laus, Barbara Collins, J. Carl Barrett, Ryan J. Hartmaier, Vassiliki Papadimitrakopoulou
Summary: The third-generation EGFR tyrosine kinase inhibitor osimertinib improves progression-free survival compared to platinum-doublet chemotherapy in patients with advanced NSCLC carrying EGFR T790M mutation. In this study, the authors used next-generation sequencing to evaluate the potential mechanisms of acquired resistance to osimertinib in patients from the AURA3 trial. Some patients had undetectable plasma EGFR T790M at disease progression and/or treatment discontinuation.
NATURE COMMUNICATIONS
(2023)
Letter
Oncology
Ling Peng, Yawen Bin, Peng Ding, Lingjuan Chen, Hao Zeng, Zelong Xu, Liyan Ji, Xuan Gao, Pian Liu, Ye Wang, Sheng Zhang, Zhongxing Liao, Xuefeng Xia, Ruiguang Zhang, Fan Tong, Xiaorong Dong
CANCER COMMUNICATIONS
(2023)
Letter
Oncology
Si-Yang Maggie Liu, Cunte Chen, Yi-Kai Zhang, Wen-Zhao Zhong, Yi-Long Wu, Si-Yang Liu, Yangqiu Li
Summary: This study identified specific TCR sequences that can predict prognosis and favorable outcomes in EGFR-mutant NSCLC patients treated with adjuvant EGFR-TKI.
BIOMARKER RESEARCH
(2023)
Article
Biochemistry & Molecular Biology
Lixin He, Jinxin Chen, Pinwei Deng, Shumei Huang, Pian Liu, Chanjuan Wang, Xinjian Huang, Yue Li, Boyu Chen, Dongni Shi, Yunyun Xiao, Xiangfu Chen, Ying Ouyang, Libing Song, Chuyong Lin
Summary: Cyst(e)ine plays a crucial role in the synthesis of glutathione and its storage in lysosomes helps cancer cells maintain redox homeostasis. Breast cancer cells upregulate MFSD12 to increase lysosomal cyst(e)ine storage, which is released to maintain GSH levels and buffer oxidative stress. mTORC1 regulates MFSD12 by phosphorylating residue T254, and this switch modulates lysosomal cyst(e)ine levels in response to oxidative stress, enhancing cell fitness. MFSD12 mutation inhibits its function and suppresses tumor progression, while its overexpression correlates with poor chemotherapy response and prognosis in breast cancer patients.
Article
Cell Biology
Liangliang Ren, Xingrong Qing, Jihong Wei, Haixin Mo, Yuanji Liu, Yaofeng Zhi, Wenjie Lu, Mingzhu Zheng, Weijian Zhang, Yuan Chen, Yuejiao Zhang, Taijin Pan, Qian Zhong, Ronggang Li, Xin Zhang, Xiaohong Ruan, Ruyuan Yu, Jun Li
Summary: This study identifies the role of DDUP microprotein in sustaining DDR signaling and cisplatin resistance in ovarian cancer cells. The study demonstrates that DDUP foci induced by DNA damage contribute to cisplatin resistance through RAD18/RAD51C and RAD18/PCNA complexes. Treatment with an ATR inhibitor disrupts the DDUP/RAD18 interaction and increases the sensitivity of ovarian cancer cells to cisplatin-based therapy.
CELL DEATH & DISEASE
(2023)
Article
Oncology
Haiqin Wang, Haohui Wang, Jiajing Chen, Pian Liu, Xiaoxiong Xiao
Summary: Studies have found that FAM111B is highly expressed in esophageal cancer tissues and promotes the progression of esophageal cancer cells by binding to GSDMA. The FAM111B/GSDMA axis also regulates the sensitivity of esophageal cancer to cisplatin. This discovery reveals a novel pathway that plays a significant role in esophageal cancer tumorigenesis and chemosensitivity.
Review
Oncology
Yang-Si Li, Guang-Ling Jie, Yi-Long Wu
Summary: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the standard treatment for non-small-cell lung cancer (NSCLC) with active EGFR mutations. However, resistance to EGFR-TKIs eventually develops, necessitating alternative treatment options for extensively pretreated patients with EGFR-mutant NSCLC. New agents, such as fourth-generation EGFR-TKIs, combination therapy with targeted drugs, and antibody-drug conjugates, have shown promising efficacy in clinical trials for this patient population. This review summarizes the current efforts in managing extensively pretreated patients with EGFR-mutant NSCLC.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2023)
Article
Medicine, Research & Experimental
Muwen Yang, Yue Li, Lingzhi Kong, Shumei Huang, Lixin He, Pian Liu, Shuang Mo, Xiuqing Lu, Xi Lin, Yunyun Xiao, Dongni Shi, Xinjian Huang, Boyu Chen, Xiangfu Chen, Ying Ouyang, Jun Li, Chuyong Lin, Libing Song
Summary: HER2-targeted therapy is the main treatment for HER2+ breast cancer, but HER2 shedding reduces the effectiveness of anti-HER2 therapy. This study found that upregulation of DPAGT1 sustains HER2 shedding and confers trastuzumab resistance. Inhibition of DPAGT1 in combination with trastuzumab treatment can block HER2 signaling and reverse resistance.
JOURNAL OF CLINICAL INVESTIGATION
(2023)
Article
Oncology
Byoung Chul Cho, Myung-Ju Ahn, Jin Hyoung Kang, Ross A. Soo, Thanyanan Reungwetwattana, James Chih-Hsin Yang, Irfan Cicin, Dong-Wan Kim, Yi-Long Wu, Shun Lu, Ki Hyeong Lee, Yong-Kek Pang, Anastasia Zimina, Chin Heng Fong, Elena Poddubskaya, Ahmet Sezer, Soon Hin How, Pongwut Danchaivijitr, Yukyung Kim, Yeji Lim, Taewon An, Hana Lee, Hae Mi Byun, Bojan Zaric
Summary: Lazertinib demonstrated significant efficacy improvement compared with gefitinib in the first-line treatment of EGFR-mutated advanced NSCLC, with a manageable safety profile. The results of this study are of great importance for improving patient outcomes and guiding clinical practice.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Letter
Oncology
Roy S. Herbst, Yi-Long Wu, Masahiro Tsuboi
JOURNAL OF CLINICAL ONCOLOGY
(2023)